New research shows gut-friendly bacteria may slow vitiligo progression, offering hope for millions with autoimmune disease.

Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...

The global dermatology lasers market is set for substantial growth, increasing from USD 1,767.8 billion in 2023 to USD ...

World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting ...

Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...

The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

An autoimmune disease characterized by skin depigmentation, vitiligo has attained many stereotypes. This dermatological ...

This Women's Day 2025, we bring you an exclusive conversation with Aastha Shah, a fearless content creator who is breaking ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

On International Women's Day, we honour the remarkable contributions of women doctors who have revolutionised the field of ...